Novo Nordisk acquires Emisphere Technologies


Novo Nordisk acquires Emisphere Technologies and obtains ownership of the Eligen® SNAC oral delivery technology

6 November 2020 – Novo Nordisk has entered into a definitive agreement to acquire Emisphere Technologies Inc., a drug delivery company with proprietary technologies, such as the Eligen® SNAC technology, that enable oral formulations of therapeutics. Novo Nordisk and Emisphere have collaborated since 2007 and Emisphere’s proprietary drug delivery technology Eligen® SNAC is used by Novo Nordisk under an existing licence agreement in the oral formulation of Novo Nordisk’s GLP-1 receptor agonist semaglutide, which is marketed and sold under the brand name Rybelsus®.

Aerial photo of NN1 and NN2, Novo Nordisk Danish headquarters in Bagsværd. Inaugurated 2014. Architects: Henning Larsen


Q3 2020: Operating profit increased by 6% in DKK and by 7% at CER

30 October - Lars Fruergaard Jørgensen, president and CEO: "We’re very satisfied with the performance in the first nine months of 2020 despite the negative impacts from COVID-19. More patients use our GLP-1 treatments, and our diabetes market leadership continues to expand. Within R&D, an important milestone was reached with the encouraging results from the phase 2b trial in cardiovascular disease with ziltivekimab, the lead candidate from Corvidia Therapeutics that was acquired this year".

Transport line glass container - Copyright SCHOTT AG


Novo Nordisk launches new 100% renewable power target for suppliers

21 September - Novo Nordisk today announced an ambitious target to ensure all its direct suppliers supply the company based on 100% renewable power by 2030. Novo Nordisk will work with all existing and new suppliers to meet the target. The plan will be presented in connection with Climate Week NYC hosted this week in association with the United Nations and the City of New York. This commitment is the next step in Novo Nordisk’s ‘Circular for Zero’ environmental strategy, which launched in April 2019 and set an ultimate ambition for the company to have zero environmental impact.

Graphic images of insulin pens


Can you recycle an insulin pen?

Recycling an insulin pen is a lot harder than it sounds. But might there come a day when all insulin pens can be re-purposed after use? And what more can we do to help solve the world’s growing plastic challenge?

Stay informed

Stay informed

Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.

Please fill in the fields below to receive our news

E-mail address

Email is required Invalid email address